Pangenomic talks up AI health system NaraCare.AI

Executive Summary

• Pangenomic Health announced the development of the NaraCare.AI platform, an AI-driven health platform designed to provide personalized alternative health product recommendations and practitioner access, leveraging existing assets like the Nara mental health app and Mindleap telehealth platform.
• The company provided specific launch timelines for its digital ecosystem: the Nara e-commerce shopping site is expected to launch in Q3 2025, followed by the full NaraCare.AI platform in Q4 2025.
• The company accelerated the expiration date of 7.5 million share purchase warrants to August 25, 2025, due to the share price meeting the $0.26 threshold for 10 consecutive trading days, with any proceeds to be used for general corporate and working capital purposes.

Key Details

• NaraCare.AI Platform Strategy:
  • The platform aims to be a trusted source for consumers and practitioners regarding personalized alternative health treatments.
  • It will provide evidence-based information on benefits, dosage, adverse effects, and drug interactions.
  • Includes an integrated online e-commerce site for purchasing alternative health products.
• Technology and Data Integration:
  • Leverages insights from the Nara mental health app (personalized insights based on medication, mood, and biological factors).
  • Integrates with the Mindleap telehealth platform for access to alternative health practitioners.
  • Utilizes Mujn diagnostic tools to track biomarkers relevant to natural remedy treatment regimens.
  • Reviews pharmacogenomics, nutrigenomics, and proteomics research data alongside individual genomic and proteomic data.
• Launch Schedule:
  • Nara e-commerce shopping site: Expected launch in the third quarter of 2025.
  • NaraCare.AI platform: Expected launch in the fourth quarter of 2025.
• Warrant Acceleration:
  • Warrants Issued: 7.5 million share purchase warrants issued on or about January 10, 2025.
  • Exercise Price: $0.13 per share.
  • Acceleration Trigger: Closing price of shares was equal to or greater than $0.26 per share for 10 consecutive trading days ending July 24, 2025.
  • New Expiration Date: August 25, 2025, at 5 p.m. PT.
  • Use of Proceeds: General corporate and working capital purposes.

Notable Quotes

• "Pangenomic Health is pleased to announce that it is developing a new AI health platform for personalized alternative health products... we believe that our NaraCare.AI platform can become the trusted source for consumers and practitioners across North America." — Maryam Marissen, President and CEO